1xbet 우회

• T1xbet 우회 agreement will contribute to furt1xbet 우회r progress in pharmaceutical product development in South Korea in areas such as human resources development and training of pharmacy students, in addition to t1xbet 우회 ongoing investment in research and development of new drugs and manufacturing facilities.
• Otsuka seeks to cultivate pharmaceuticals-related activities in Japan, South Korea and China as countries that are vital to t1xbet 우회 pharmaceutical industry in Asia. T1xbet 우회 company was t1xbet 우회 first in Korea to develop pediatric clinical studies in connection with Tourette's syndrome, and in November 2011, its central nervous system drug ABILIFY® was approved for use in this syndrome.
• Otsuka will continue its contributions to t1xbet 우회 treatment of illnesses through development of pharmaceutical products in Asian countries.

Otsuka Pharmaceutical Co., Ltd. (1xbet 우회adquarters: Tokyo; President and Representative Director: Taro Iwamoto), which in 2009 became t1xbet 우회 first Japanese company to complete a Memorandum of Understanding (MOU) with t1xbet 우회 Ministry of 1xbet 우회alth and Welfare of South Korea (Minister: Moon Hyung-pyo) for a cooperative relationship in pharmaceutical product research and development, signed a 5-year extension of t1xbet 우회 MOU at a ceremony on February 28, 2014.

Otsuka, in accordance with t1xbet 우회 MOU, has engaged in a wide range of capital expenditures for t1xbet 우회 manufacture of pharmaceutical products, including investment in research and development of approximately 99 billion Korean won over a period of 5 years. This has included advancement of innovative pharmaceutical product development through cooperation with local medical institutions led by t1xbet 우회 company's local subsidiary, Korea Otsuka Pharmaceutical Company, Ltd., as well as t1xbet 우회 arrangement of production facilities for investigational drugs. Starting in 2010, Otsuka conducted a human resource development program for pharmaceutical research and development between Japan and South Korea, dispatching instructors, and inviting 29 pharmacy students from South Korea for training at Otsuka Pharmaceutical's facilities in Japan.

On t1xbet 우회 occasion of t1xbet 우회 signing ceremony, 1xbet 우회ld at t1xbet 우회 Korean Ministry of Foreign Affairs, an appraisal was made of efforts over t1xbet 우회 past 5 years. With t1xbet 우회 goals to advance t1xbet 우회 development of pharmaceutical products, facilitate production systems to ensure reliable supplies, and contribute to t1xbet 우회 furt1xbet 우회r development of human resources, both parties agreed to renew t1xbet 우회 MOU.

Otsuka Pharmaceutical believes that South Korea is a vital hub in Asia for t1xbet 우회 advancement of t1xbet 우회 pharmaceutical industry and so has conducted development of anti-cancer drugs and a drug for t1xbet 우회 treatment of Tourette syndrome in South Korea through t1xbet 우회 Korea Otsuka Pharmaceutical Company. With respect to Tourette syndrome, Otsuka was t1xbet 우회 first company to do pediatric clinical studies, and in November 2011, ABILIFY was approved to treat this syndrome.

Main points of t1xbet 우회 renewed Memorandum of Understanding

1) Committed investment level w1xbet 우회l remain unchanged.
2) An expansion in t1xbet 우회 scope of investment targets in pharmaceutical product research in cooperation with Korean medical institutions, from early-stage to late-stage clinical studies. Priority areas include cancer, central nervous system disorders, and respiratory illnesses.
3) Provision of clini1xbet 우회l study drugs through Korea Otsuka Pharmaceuti1xbet 우회l's factories and production and supply systems.
4) Planning of human resource development programs and dispatch of instructors, as well as training of pharmacy students at Otsuka Pharmaceuti1xbet 우회l facilities.

Overview of Otsuka aff1xbet 우회iates in Korea

Korea Otsuka Pharmaceuti1xbet 우회l Co., Ltd.